As shown in Supplemental Figure 8, A–C, KIFC2-overexpressing cells exhibited increased sensitivity to the antimetabolite chemotherapy agent capecitabine, which is effective for the clinical treatment of breast cancer (35). Here, KIFC2 is linked to breast carcinoma.